Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 262

Similar articles for PubMed (Select 23014526)

1.

Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.

van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK.

Clin Cancer Res. 2012 Nov 15;18(22):6306-14. doi: 10.1158/1078-0432.CCR-12-0406. Epub 2012 Sep 26.

2.

89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GA, Lub-de Hooge MN, Schröder CP, de Vries EG.

J Nucl Med. 2010 May;51(5):761-7. doi: 10.2967/jnumed.109.071043. Epub 2010 Apr 15.

3.

89Zr-bevacizumab PET imaging in primary breast cancer.

Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, van Dam GM, van der Meulen SB, de Jong JR, Bart J, de Vries J, Jansen L, de Vries EG, Schröder CP.

J Nucl Med. 2013 Jul;54(7):1014-8. doi: 10.2967/jnumed.112.117218. Epub 2013 May 7.

4.

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN.

J Nucl Med. 2007 Aug;48(8):1313-9. Epub 2007 Jul 13.

5.

Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.

Jaeger-Lansky A, Cejka D, Ying L, Preusser M, Hoeflmayer D, Fuereder T, Koehrer S, Wacheck V.

Cancer Biol Ther. 2010 Jun 1;9(11):919-27. Epub 2010 Jun 18.

6.

Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, Timmer-Bosscha H, Lub-de Hooge MN, Schröder CP, de Vries EG.

Cancer Res. 2013 Jun 1;73(11):3347-55. doi: 10.1158/0008-5472.CAN-12-3518. Epub 2013 Apr 11.

7.

Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.

Terwisscha van Scheltinga AG, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot L, Gaykema SB, Lub-de Hooge MN, Kosterink JG, de Vries EG, Schröder CP.

Eur J Cancer. 2014 Sep;50(14):2508-16. doi: 10.1016/j.ejca.2014.06.008. Epub 2014 Jul 12.

PMID:
25027745
8.

Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.

Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, Endo K.

Cancer Sci. 2011 Jan;102(1):117-21. doi: 10.1111/j.1349-7006.2010.01763.x. Epub 2010 Nov 10.

PMID:
21070475
9.

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.

Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG.

J Nucl Med. 2015 Jan;56(1):63-9. doi: 10.2967/jnumed.114.144840. Epub 2014 Dec 4.

PMID:
25476536
10.

PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.

Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW.

Int J Cancer. 2011 Feb 15;128(4):920-6. doi: 10.1002/ijc.25409.

11.

Combined treatment strategies for microtubule stabilizing agent-resistant tumors.

Broggini-Tenzer A, Sharma A, Nytko KJ, Bender S, Vuong V, Orlowski K, Hug D, O'Reilly T, Pruschy M.

J Natl Cancer Inst. 2015 Feb 17;107(4). pii: dju504. doi: 10.1093/jnci/dju504. Print 2015 Apr.

PMID:
25694444
12.

(89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.

Oude Munnink TH, Korte MA, Nagengast WB, Timmer-Bosscha H, Schröder CP, Jong JR, Dongen GA, Jensen MR, Quadt C, Hooge MN, Vries EG.

Eur J Cancer. 2010 Feb;46(3):678-84. doi: 10.1016/j.ejca.2009.12.009. Epub 2009 Dec 24.

PMID:
20036116
13.

In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.

Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA.

J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10.

14.

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.

Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma Y, Zhang J.

Tumour Biol. 2012 Oct;33(5):1349-62. doi: 10.1007/s13277-012-0383-6. Epub 2012 Apr 11.

PMID:
22492237
15.

Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.

Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67. doi: 10.1007/s00259-008-0774-5. Epub 2008 May 20.

PMID:
18491091
16.

18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.

Aide N, Kinross K, Cullinane C, Roselt P, Waldeck K, Neels O, Dorow D, McArthur G, Hicks RJ.

J Nucl Med. 2010 Oct;51(10):1559-64. doi: 10.2967/jnumed.109.073288. Epub 2010 Sep 16.

17.

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.

Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V.

Cancer Biol Ther. 2008 Sep;7(9):1377-85. Epub 2008 Sep 2.

18.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

19.

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M.

J Clin Oncol. 2009 Jun 1;27(16):2697-704. doi: 10.1200/JCO.2008.18.8383. Epub 2009 Apr 20.

20.

Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.

Shao M, Hollar S, Chambliss D, Schmitt J, Emerson R, Chelladurai B, Perkins S, Ivan M, Matei D.

Mol Cancer Ther. 2012 Jul;11(7):1576-86. doi: 10.1158/1535-7163.MCT-11-0961. Epub 2012 Jun 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk